Get the best from this site

We would like to place cookies on your computer to help us make this website better. For more information, including how to turn cookies off, see more about cookies. Or simply continue below:

Continue

Coventry and Warwickshire Innovation Programme

Pages in Coventry and Warwickshire Innovation Programme

  1. Coventry and Warwickshire Innovation Programme
  2. Innovation Programme - Torc2 Case Study
  1. Innovation Programme - BHR Pharmaceuticals Case Study
  2. Innovation Programme - Enable iD Case Study

Innovation Programme - BHR Pharmaceuticals Case Study

Business ready BHR

The Coventry and Warwickshire Innovation Programme

Development of new diabetes treatment to commence local trials.

BHR Pharmaceuticals based in Nuneaton are taking forward the development of a piece of technology known as FREMS for the management and treatment of diabetic wounds and peripheral neuropathies. The FREMS (Frequency Rhythmic Electrical Modulation System) device uses modulated frequency pulses to improve the supply of oxygen to nerve cells with the aim of reducing pain. Using specialist NHS staff BHR will undertake pilot clinical trials at the George Eliot Hospital in Nuneaton in order to generate evidence to push for further multi centre trials across the NHS and ultimately see the technology be adopted for treating diabetic neuropathies. If successful the use of FREMS could help reduce the financial burden the NHS experiences dealing with diabetic conditions and also provide patients with a non-invasive approach that helps provide pain relief without the need for drug treatment and prevent further debilitating illnesses associated with diabetes.

Bharat Vadukul, Director, BHR said: "The main treatments for painful diabetic neuropathy remain management of the underlying diabetes and drugs for the relief of pain. Despite the significant individual and social burden associated with diabetic neuropathy, its treatment remains unsatisfactory."
    
"Many therapies have been the subject of clinical trials for diabetic neuropathy and painful diabetic neuropathy. However, there are currently no FDA-approved therapies for diabetic neuropathy so our aim is to work to that and provide a treatment that is clinically proved and works."

Facts

  • Company: BHR Pharmaceuticals
  • Location: Nuneaton
  • Sector: Manufacturing
  • Technology Focus: Medical
  • Grant Awarded: £33,000
  • Jobs Being Created: 2
BHR were working with the University of Warwick Science Park's Business Ready programme who then referred them to Coventry City Council resulting in a grant being awarded under the Coventry & Warwickshire Innovation Programme which is part funded by the European Regional Development Fund. 

Richard Middleton, Innovation Development Officer, Coventry City Council said: "The work BHR are doing could bring about the introduction of an exciting new emerging medical technology to the NHS that could bring cost savings and better outcomes for patients.    
"Our grant funding will help BHR undertake pilot clinical trials in Coventry & Warwickshire that should provide further evidence to support the case for the NHS to adopt the technology. The results of the trials should generate interest from specialists in the clinical community."

The Coventry & Warwickshire Innovation Programme supports local SMEs to develop innovative products and services which are new to the market. If you are interested in the programme please email us at: innovation@coventry.gov.uk

Is there anything wrong with this page?